The first in the world to work on the innovative technique of adaptive immunotherapy to treat cancer, recently hailed worldwide as a potentially ‘extraordinary’ development, was Israeli Prof. Zelig Eshhar of the Weizmann Institute.
In that same sense, we can mention a study on cancer in patients suffering from a form of leukemia and saw their diseases in remission after they were treated with genetically modified T cells have deep roots in Israel.
In an article published in the journal Science Translational Medicine, a team at the Abramson Cancer Center at the University of Pennsylvania and Perelman School of Medicine reported that 27 of the 29 patients with advanced blood cancer saw their cancers go into remission or disappear altogether when they received the genetically modified T cells that were equipped with synthetic molecules called chimeric antigen receptors, or the CARs. These T cells were able to attack and destroy tumor cells, specifically those that were responsible for the acute lymphoblastic leukemia that the patients suffered.
According to officials at the Fred Hutchinson Cancer Research Center where the research was conducted, trial patients, some of whom were told in 2013 that they were only a few months old, not only survived, but now, after therapy, ‘they have no sign of disease’.
The Times of Israel |Israel News